AZNAcerta Pharma BVRunning, no new patients
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Mantle Cell Lymphoma (MCL)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 124 (final count)
- Started
- Mar 2, 2015
- Main results expected
- Dec 4, 2020
- Fully finished
- Sep 6, 2026
- Results posted
- Oct 19, 2018
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL.
Measured over: From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02213926 · record last updated 2026-08-04 · checked 2026-11-09 15:47 UTC